CJC-1295 Mechanism of Action: Full Pathway From Injection to IGF-1 Output

Native GHRH Physiology: The Baseline CJC-1295 Modifies

The GH axis starts in the hypothalamus. GHRH neurons in the arcuate nucleus release GHRH (also called GRF or somatoliberin) in episodic bursts that travel through the hypophyseal portal system to the anterior pituitary 1. These bursts coordinate with somatostatin withdrawal to produce the characteristic pulsatile GH secretion pattern, with the largest pulses occurring during slow-wave sleep 2.

The GHRH Receptor

GHRH binds a 423-amino-acid class B1 G protein-coupled receptor (GHRHR) expressed on somatotroph cell membranes 3. Loss-of-function mutations in this receptor cause isolated GH deficiency, as documented in the "little" mouse model and in human kindreds with dwarfism of Sindh 4. The receptor's extracellular domain recognizes GHRH residues 1 through 29. That is the minimum fragment needed for full receptor activation.

Rapid Degradation of Native GHRH

Native GHRH(1-44) is degraded within minutes by dipeptidyl peptidase-IV (DPP-IV), which cleaves the Tyr1-Ala2 bond to produce inactive GHRH(3-44) 5. The circulating half-life of native GHRH is approximately 7 minutes. This rapid clearance is the core pharmacokinetic problem that CJC-1295 was engineered to solve.

CJC-1295 Molecular Design: Four Substitutions and a Linker

CJC-1295 is built on the GRF(1-29)NH₂ backbone with four amino acid substitutions at positions 2, 8, 15, and 27 6. Each substitution serves a specific protective or functional purpose.

The Four Key Substitutions

Position 2 replaces Ala with D-Ala, rendering the N-terminal bond resistant to DPP-IV cleavage. This single change extends the peptide's half-life by roughly 5-fold compared to native GRF 5. Position 8 replaces Asn with Gln, preventing deamidation that reduces receptor affinity during storage and circulation. Position 15 replaces Gly with Ala to improve alpha-helical stability, which protects the peptide from trypsin-like proteases. Position 27 replaces Met with Leu, eliminating the methionine sulfoxide oxidation pathway that degrades activity in aqueous solution 7.

The combined result is a peptide called modified GRF(1-29) or "mod-GRF" that retains full GHRHR agonist activity while resisting the three main degradation pathways: DPP-IV cleavage, deamidation, and oxidation.

The Drug Affinity Complex (DAC)

The DAC variant adds a maleimidopropionic acid (MPA) reactive linker to Lys at position 30 of the peptide chain. After subcutaneous injection, this linker undergoes a bioconjugation reaction with Cys34 on serum albumin, forming a stable thioether bond 6. Because albumin has a circulating half-life of approximately 19 days, the CJC-1295/albumin conjugate achieves a functional peptide half-life of 6 to 8 days. This is more than a 1,000-fold extension over native GHRH.

The bioconjugation reaction occurs within minutes of injection. In the Teichman et al. Trial, greater than 90% of circulating CJC-1295 was albumin-bound within 15 minutes of subcutaneous dosing 6.

Receptor Binding and Intracellular Signaling

Once CJC-1295 reaches pituitary somatotrophs (whether free or albumin-bound, since the albumin conjugate retains receptor access), it engages the GHRHR through the same binding interface as native GHRH 8.

The cAMP/PKA Cascade

GHRHR activation triggers the canonical Gαs signaling pathway. The receptor couples to stimulatory G-protein alpha subunit (Gαs), which activates adenylyl cyclase on the somatotroph membrane 3. Adenylyl cyclase converts ATP to cyclic AMP (cAMP). Intracellular cAMP then activates protein kinase A (PKA).

PKA phosphorylates two functional targets. First, it phosphorylates the transcription factor CREB (cAMP response element binding protein), which translocates to the nucleus and drives GH1 gene transcription 9. Second, PKA phosphorylates components of the exocytic machinery on GH-containing secretory granules, triggering calcium-dependent vesicle fusion and immediate GH release into pituitary venous blood 10.

Calcium Channel Involvement

The cAMP/PKA pathway also opens voltage-gated calcium channels (primarily L-type) on the somatotroph membrane 10. The resulting calcium influx amplifies exocytosis and is required for the full GH secretory response. This is why calcium channel blockers can blunt GH responses to GHRH stimulation testing.

Pit-1 and Somatotroph Proliferation

Beyond acute GH release, prolonged GHRHR signaling activates the Pit-1 (POU1F1) transcription factor pathway, which drives somatotroph differentiation and proliferation over weeks to months 11. This means chronic CJC-1295 exposure may increase the total somatotroph population in the anterior pituitary, a trophic effect distinct from pulse amplification.

GH Secretion Pattern: Amplified Pulsatility, Not Flat-Line Elevation

A critical pharmacodynamic distinction separates CJC-1295 from exogenous GH injections. Exogenous recombinant GH produces a single pharmacokinetic spike followed by trough. CJC-1295 preserves the endogenous pulsatile GH pattern while increasing pulse amplitude.

Clinical Evidence of Preserved Pulsatility

In the Teichman et al. Dose-ranging trial (N=33 healthy subjects), CJC-1295 DAC at doses from 30 to 60 μg/kg produced 2- to 10-fold increases in mean GH concentrations sustained over multiple days, with preservation of episodic GH pulsatility 6. Twenty-four-hour GH sampling showed amplified pulse peaks during nighttime, consistent with somatostatin withdrawal potentiation rather than tonic secretion.

Why Pulsatility Matters

GH receptor signaling in target tissues (liver, muscle, bone, adipose) depends on pulse amplitude and interpulse trough periods. Continuous GH exposure downregulates the JAK2/STAT5 signaling pathway and reduces hepatic IGF-1 output 12. By preserving troughs between pulses, CJC-1295 maintains GH receptor sensitivity. This is why GHRH analogs can produce physiologic GH patterns that exogenous GH injections cannot replicate.

Downstream Effects: The GH → IGF-1 Axis

GH secreted in response to CJC-1295 enters the systemic circulation and binds the GH receptor (GHR) on hepatocytes and other target cells.

Hepatic IGF-1 Production

In the liver, GH binding activates the JAK2/STAT5b pathway, driving transcription of the IGF1 gene 13. The liver produces approximately 75% of circulating IGF-1. In the Teichman et al. Trial, IGF-1 levels rose 1.5- to 3-fold above baseline and remained elevated for up to 8 to 14 days after a single CJC-1295 DAC injection, consistent with the peptide's extended half-life 6.

IGF-1 Binding Proteins

Circulating IGF-1 is bound (greater than 99%) in ternary complexes with IGFBP-3 and the acid-labile subunit (ALS), both of which are also GH-dependent 14. CJC-1295-induced GH secretion increases IGFBP-3 and ALS in parallel with IGF-1, extending the functional half-life of IGF-1 from approximately 10 minutes (free) to 12 to 16 hours (ternary-bound).

Tissue-Level IGF-1 Actions

At peripheral tissues, IGF-1 binds the IGF-1 receptor (a tyrosine kinase receptor), activating PI3K/Akt and Ras/MAPK pathways 15. These cascades drive:

• Skeletal muscle: Protein synthesis via mTOR activation and satellite cell recruitment
• Bone: Osteoblast proliferation and collagen synthesis at the growth plate and periosteum
• Adipose tissue: Lipolysis through reduced insulin sensitivity in adipocytes
• Connective tissue: Fibroblast proliferation and extracellular matrix synthesis

Negative Feedback Loops: Built-In Safety Brakes

The GH/IGF-1 axis includes multiple feedback circuits that limit CJC-1295's effect ceiling.

Somatostatin Inhibition

Rising GH levels stimulate somatostatin (SST) neurons in the periventricular nucleus of the hypothalamus. SST binds somatostatin receptors (SSTR2 and SSTR5) on somatotrophs, activating inhibitory Gi proteins that suppress cAMP production and close calcium channels 16. This is the primary brake. Even with continuous GHRHR agonism from CJC-1295, somatostatin release during interpulse intervals enforces GH troughs.

IGF-1 Feedback

IGF-1 itself feeds back at two levels. At the pituitary, IGF-1 suppresses GH gene transcription through IGF-1 receptor activation on somatotrophs 17. At the hypothalamus, IGF-1 increases somatostatin tone and decreases GHRH release from arcuate neurons. These dual feedback loops explain why CJC-1295 produces dose-dependent but self-limiting GH elevation. Supraphysiologic GH "runaway" is prevented by the very IGF-1 the peptide generates.

GH Short-Loop Feedback

GH also acts directly on hypothalamic neurons to suppress its own release through short-loop feedback 18. This adds a third layer of auto-regulation that exogenous GH bypasses entirely but CJC-1295 preserves.

CJC-1295 With DAC vs. Without DAC: Pharmacokinetic Divergence

The two commercially available forms of CJC-1295 differ only in the presence or absence of the MPA/DAC linker, but this creates substantially different pharmacokinetic profiles.

CJC-1295 DAC (With DAC)

After subcutaneous injection, bioconjugation with albumin occurs within minutes. The resulting conjugate has a terminal half-life of 5.8 to 8.1 days 6. GH elevation begins within 2 hours and persists for up to 6 days. IGF-1 remains above baseline for 8 to 14 days. Standard dosing is once weekly at 1 to 2 mg subcutaneously.

CJC-1295 Without DAC (Mod-GRF 1-29)

Without the linker, the peptide cannot bind albumin. Its half-life is approximately 30 minutes (longer than native GHRH due to the four substitutions, but far shorter than the DAC variant) 7. GH release is a single sharp pulse lasting 1 to 2 hours. Standard dosing is 100 to 300 μg subcutaneously, one to three times daily, often timed to coincide with natural GH pulse windows (bedtime, post-exercise, fasting morning).

Clinical Implications

The DAC variant provides convenience and sustained IGF-1 but raises baseline GH between pulses, potentially reducing receptor sensitivity over time. The no-DAC variant better mimics a single physiologic GH bolus but requires multiple daily injections. Most compounding pharmacy protocols pair mod-GRF (no DAC) with ipamorelin (a ghrelin-mimetic GH secretagogue) to exploit combination between GHRH-pathway and GHS-R pathway activation 19.

Combination With GH Secretagogues: GHRH + Ghrelin Pathways

CJC-1295 acts on the GHRH receptor. A separate class of peptides, the growth hormone secretagogues (GHS), acts on the GHS-R1a (ghrelin receptor). The two pathways converge on the somatotroph but through distinct intracellular mechanisms 20.

Mechanistic Basis for Combination

GHRH receptor activation raises cAMP. Ghrelin/GHS-R1a activation raises intracellular calcium through PLC/IP3 and also inhibits potassium channels, depolarizing the somatotroph membrane 20. The cAMP and calcium pathways are multiplicative, not merely additive, for GH exocytosis. Co-administration of GHRH and a GHS produces GH peaks 5- to 10-fold higher than either agent alone 21.

Somatostatin Gate

Both pathways are subject to somatostatin inhibition, but ghrelin-mimetics partially antagonize somatostatin's effect on calcium channels 20. This means the combination of CJC-1295 + ipamorelin can partially override somatostatin tone during interpulse periods, producing larger GH peaks even when feedback braking is active.

Safety Pharmacology Considerations

Because CJC-1295 works through the endogenous GH axis rather than replacing GH directly, its safety profile differs from recombinant GH.

Dose-Ceiling Effect

The triple negative feedback system (somatostatin, IGF-1, GH short-loop) creates a pharmacologic ceiling. In the Teichman et al. Study, doses above 60 μg/kg did not produce proportionally greater GH elevation 6. This ceiling may reduce (though not eliminate) the risk of acromegalic-range GH/IGF-1 exposure compared to supraphysiologic exogenous GH dosing.

Cortisol and Prolactin Cross-Reactivity

GHRH receptors are expressed primarily on somatotrophs. CJC-1295 does not activate corticotrophs or lactotrophs at standard doses, so cortisol and prolactin levels remain unaffected 6. This selective somatotroph targeting distinguishes GHRH analogs from GH secretagogues like hexarelin, which can raise cortisol and prolactin through GHS-R1a activation on non-somatotroph cell types 19.

Monitoring Implications

Clinicians monitoring CJC-1295 therapy should track serum IGF-1 (as a stable surrogate for integrated GH exposure), fasting glucose (GH is diabetogenic), and HbA1c for patients with insulin resistance 22. Random GH levels are unreliable because CJC-1295 preserves pulsatility, and a random sample may land on a peak or trough.

Patients on CJC-1295 DAC should have IGF-1 levels drawn 3 to 4 days post-injection (steady-state window) and dose-adjusted to keep IGF-1 within the age-adjusted reference range published by the Endocrine Society 22.